Amgen Aranesp Price Is In Middle Of Procrit Range; Reimbursement Likely
Executive Summary
Amgen is launching the anemia agent Aranesp at a price falling in the middle of the range for Johnson & Johnson's erythropoietin brand Procrit.
You may also be interested in...
Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit
Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)
Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit
Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)
Aranesp Bi-Weekly Dose Can Substitute For Once-Weekly Procrit - Labeling
Amgen's novel erythropoiesis stimulating protein Aranesp is labeled for administration once every two weeks when it is replacing a once-weekly dose of Johnson & Johnson's Procrit (epoetin alfa).